FOOTNOTES 1. Freeman LM and Rush JE. Nutrition and cardiomyopathy: lessons from spontaneous animal models. Curr Heart Fail Rep. 2007;4(2):84-90. 2. Hamlin RL and Buffington CAT. Nutrition and the heart. Veterinary Clinics of North America: Small Animal Practice. 1989;19(3):527-538. 3. Freeman LM. Interventional nutrition for cardiac disease. Clinical Techniques in Small Animal Practice. 1998;13(4):232-237. 4. Rocha M and Victor VM. Targeting antioxidants to mitochondria and cardiovascular diseases: the effects of mitoquinone. Med Sci Monit. 2007;13(7):RA132-RA145. 5. Bolcal CC, Yildirim V, Doganci S, et al. Do N-acetylcystein, ß-glucan, and coenzyme Q10 mollify myocardial ischemia-reperfusion injury? The Heart Surgery Forum. 2007;10(3):E222-E227. 6. Bolcal CC, Yildirim V, Doganci S, et al. Do N-acetylcystein, ß-glucan, and coenzyme Q10 mollify myocardial ischemia-reperfusion injury? The Heart Surgery Forum. 2007;10(3):E222-E227. 7. Haas RH. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion. 2007;7S:S136-S145. 8. Haas RH. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion. 2007;7S:S136-S145. 9. Bolcal CC, Yildirim V, Doganci S, et al. Do N-acetylcystein, ß-glucan, and coenzyme Q10 mollify myocardial ischemia-reperfusion injury? The Heart Surgery Forum. 2007;10(3):E222-E227. 10. Pepe S, Marasco SF, Haas SJ, et al. Coenzyme Q10 in cardiovascular disease. Mitochondrion. 2007;7S:S154-S167. 11. Haas RH. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion. 2007;7S:S136-S145. 12. DeFrancesco TC, Atkins CE, and Keene BW. Myocardial infarction complicating management of congestive heart failure in a dog. J Am Anim Hosp Assoc. 1996;32(1):68-72. 13. Driehys S, Van Winkle TJ, Sammarco CD, et al. Myocardial infarction in dogs and cats: 37 cases (1985-1994). J Am Vet Med Associ. 1998;213(10):1444-1448. 14. Tarnow I, Falk T, Tidholm A, et al. Hemostatic biomarkers in dogs with chronic congestive heart failure. J Vet Intern Med. 2007;21:451-457. 15. Lin CS, Liu CY, Sun YL, et al. Alteration of endogenous antioxidant enzymes in naturally occurring hypertrophic cardiomyopathy. Biochem Mol Biol Int. 1997;43(6):1253-1263. 16. Baumer AT, Flesch M, Wang X, et al. Antioxidative enzymes in human hearts with idiopathic dilated cardiomyopathy. J Mol Cell Cardiol. 2000;32(1):121-130. 17. Sam F, Kerstetter DL, Pimental DR, et al. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail. 2005;11(6):473-480. 18. Pepe S, Marasco SF, Haas SJ, et al. Coenzyme Q10 in cardiovascular disease. Mitochondrion. 2007;7S:S154-S167. 19. Pepe S, Marasco SF, Haas SJ, et al. Coenzyme Q10 in cardiovascular disease. Mitochondrion. 2007;7S:S154-S167. 20. Haas RH. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion. 2007;7S:S136-S145. 21. Nukui K, Matsuoka Y, Yamagishi T, et al. Safety assessment of PureSorb-Q ™40 in healthy subjects and serum coenzyme Q10 level in excessive dosing. J Nutri Sci Vitamino. 2007;53:198-206. 22. Pepe S, Marasco SF, Haas SJ, et al. Coenzyme Q10 in cardiovascular disease. Mitochondrion. 2007;7S:S154-S167. 23. Shalansky S, Lynd L, Richardson K, et al. Risk of warfarin-related bleeding events and supratherapeutic International Normalized Ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. 2007;27(9):1237-1247. 24. Zaghloul AA, Gurley B, Khan M, et al. Bioavailability assessment of oral coenzyme Q10 formulations in dogs. Drug Development and Industrial Pharmacy. 2002;28(10):1195-1200. 25. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001 Jan 16;212(2):233-46. 26. Hathcock JN and Shao A. Risk assessment for coenzyme Q10 (ubiquinone). Regulatory Toxicology and Pharmacology. 2006;45:282-288. <HOME>
